化合物SB-265610
|
|
|
- CAS号:
- 211096-49-0
- 英文名:
- GSK-CXCR2
- 英文别名:
- GSK-CXCR2;SB 265610;SB265610 >=98% (HPLC);N-(2-Bromophenyl)-N'-(7-cyano-1H-benzotriazol-4-yl)urea;Urea, N-(2-bromophenyl)-N'-(4-cyano-1H-benzotriazol-7-yl)-;1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d] [1,2,3]triazol-7-yl)urea;CXCR,nonpeptide,inhibit,Inhibitor,SB-265610,inflammation,recruitment,Delay,SB 265610,healing,neutrophil,SB265610,wound,CXC chemokine receptors
- 中文名:
- 化合物SB-265610
- 中文别名:
- 化合物SB-265610;SB 265610,CXCR2拮抗剂
- CBNumber:
- CB71872298
- 分子式:
- C14H9BrN6O
- 分子量:
- 357.16
- MOL File:
- 211096-49-0.mol
|
|
|
化合物SB-265610化学性质
-
沸点:
-
527.0±45.0 °C(Predicted)
-
|
-
密度:
-
1.77±0.1 g/cm3(Predicted)
-
|
-
储存条件:
-
2-8°C
-
|
-
溶解度:
-
DMSO: soluble15mg/mL, clear
-
|
-
酸度系数(pKa):
-
6.13±0.40(Predicted)
-
|
-
形态:
-
powder
-
|
-
颜色:
-
white to light brown
-
|
化合物SB-265610性质、用途与生产工艺
SB-265610 是一种选择性的竞争性非肽变构 CXCR2 拮抗剂。SB-265610 阻断大鼠 CINC-1 诱导的钙动员和中性粒细胞趋化性，IC50 分别为 3.7 nM 和 70 nM。
In vitro, SB-265610 antagonizes rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization,
IC
50
of 3.7 nM, and rat neutrophil chemotaxis in a concentration-dependent manner,
IC
50
of 70 nM. SB-265610 reduces the antiapoptotic effect of CINC-1 to the levels of those untreated with CINC-1.
SB-265610 (100 mg/kg/day; oral administration; daily; for 5 days; CXCR2 wild type mice) treatment during the wound repair process markedly delays healing parameters in CXCR2 wild type mice.
|
Animal Model:
|
Wild type mice with nitrogen mustard
|
|
Dosage:
|
100 mg/kg/day
|
|
Administration:
|
Oral administration; daily; for 5 days
|
|
Result:
|
Markedly impaired the wound healing process.
|
化合物SB-265610
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/01/25 | HY-50688 | SB-265610 | | 1 mg | 600元 |
| 2024/01/25 | HY-50688 | 化合物SB-265610
SB-265610 | 211096-49-0 | 5 mg | 1500元 |
211096-49-0, 化合物SB-265610 相关搜索:
3-苯基磺酰基-8-(哌嗪-1-基)喹啉 N/A INARIGIVIRSOPROXIL SBI-993;SBI993;SBI993 SB-649868 14-甲基-20-氧杂-5,7,14,27-四氮杂四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2,4,6(27),8,10,12(26),16,21,23-十烯 4-(4-氟苯基)-2-(4-甲基亚磺酰基苯基)-5-(4-吡啶基)-1H-咪唑 SB204741 N/A
- 药靶配体
- 标准品
- C14H9BrN6O
- SB 265610,CXCR2拮抗剂
- 化合物SB-265610
- 211096-49-0
- CXCR,nonpeptide,inhibit,Inhibitor,SB-265610,inflammation,recruitment,Delay,SB 265610,healing,neutrophil,SB265610,wound,CXC chemokine receptors
- SB265610 >=98% (HPLC)
- Urea, N-(2-bromophenyl)-N'-(4-cyano-1H-benzotriazol-7-yl)-
- 1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d] [1,2,3]triazol-7-yl)urea
- SB 265610
- N-(2-Bromophenyl)-N'-(7-cyano-1H-benzotriazol-4-yl)urea
- GSK-CXCR2